[DOI] [PubMed] [Google Scholar] 38.McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, Sills GJ, Marson T, Jia X, de Bakker PI, Chinthapalli K, Molokhia M, Johnson MR, OConner GD, Chalia E, Alhusaini S, Shianna KV, Radtke RA, Keinzen EL, Walley N, Pandolfo M, Pichler W, Park BK, Depondt C, Sisodiya SM, Goldstein DB, Deloukas P, Delanty N, Cavalleri GL, Pirmohamed M
Ethics declarations Sources of support The research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award numbers UH2AR076719, UH3AR076719, U19AR076737, and F32AR081139, and through R01AR070198 and R01AR063705
4.2.1 Immune checkpoint inhibitor (ICI) therapies in HCC In recent years, ICI therapies have been well recognized as a main component in systemic first-line treatment of HCC due to considerably less systemic side effects and more durable responses compared with other conventional therapies (He and Xu, 2020)
N.GabrielE.Abida-IslamP.Mller-SchiffmannA.et al
Is it free of additives
